Concepedia
Statistics
Publications
8
Citations
1.9K
H-Index
Active since
2012
Affiliations
Biogen (United States)(Current)
Cleveland Clinic
Charles University
Ruhr University Bochum
St. Josef-Hospital
Mark Novas is an author at Biogen (United States) specializing in multiple sclerosis therapy, fumarate therapy, and multiple sclerosis.
Publications per year
2012–2016
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text
Medicine, Neurology, Pharmacology +6
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold, Douglas L. Arnold, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2016 · 151 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +17
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text
Life Sciences, Immunology, Pharmacology +14
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience
Ralf Gold, J. Theodore Phillips, Eva Havrdová et al. · Neurology and Therapy · 2015 · 99 citations · Full text
Medicine, Obstetrics, Pharmacotherapy +13
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
Michael Hutchinson, Robert J. Fox, David H. Miller et al. · Journal of Neurology · 2013 · 83 citations
Life Sciences, Neurology, Pharmacotherapy +7
1–5 of 8